Takahiro Ozawa

发表

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab

K. Naoki, H. Ishiyama, M. Katagiri, 2020, Thoracic cancer.

First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study

K. Naoki, Takashi Sato, S. Igawa, 2021, Investigational New Drugs.

Significance of Immune Checkpoint Inhibitors in Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy Prior to the Approval of Durvalumab

K. Naoki, H. Ishiyama, M. Katagiri, 2019 .

Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer

N. Masuda, J. Sasaki, Masayuki Shirasawa, 2016, Molecular and clinical oncology.

Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors

K. Naoki, M. Katagiri, S. Igawa, 2020, Investigational New Drugs.

Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study

K. Naoki, M. Katagiri, S. Igawa, 2019, Thoracic cancer.

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

K. Naoki, Takashi Sato, S. Igawa, 2021, Cancer management and research.

First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study

K. Naoki, Takashi Sato, S. Igawa, 2021, Investigational New Drugs.

Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations

K. Naoki, M. Katagiri, S. Igawa, 2018, Oncology.

Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease

K. Naoki, M. Katagiri, S. Igawa, 2018, Cancer management and research.

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status

K. Naoki, M. Katagiri, S. Igawa, 2018, Thoracic cancer.

Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status

K. Naoki, M. Katagiri, S. Igawa, 2018, Oncology.